Generics supply nine out of every 10 prescriptions in the U.S. and are generally much cheaper than brand-name drugs. But those savings depend on how quickly generics can enter the market — and a pending Supreme Court case, Hikma v. Amarin, could slow that process.
The dispute concerns Vascepa, a prescription treatment made from purified fish oil for certain heart-disease patients, and a generic maker, Hikma. At issue is “skinny labeling,” the practice by which a generic drug receives FDA approval to sell only the non‑patented uses of a drug. Skinny labels are intended to let generics avoid some patent fights and reach patients sooner with lower-cost alternatives.
Over the past decade more than two dozen generics have used skinny labeling, including copies of blockbuster drugs such as Crestor. One study estimated skinny labeling saved Medicare nearly $15 billion from 2015 to 2021. After some Vascepa uses lost patent protection, Hikma launched a generic in 2020 with a skinny label that covered only the unpatented indication. Amarin, Vascepa’s maker, sued, saying Hikma’s marketing encouraged prescriptions for still‑patented uses and therefore induced infringement.
Hikma’s supporters — more than 70 legal scholars and the U.S. solicitor general among them — argue that Hikma’s statements were routine marketing and labeling communications that should not expose generic firms to sweeping patent liability. They say skinny labeling was designed to allow generics to coexist with remaining patent protections without triggering costly lawsuits for ordinary product descriptions. A federal appeals court sided with Amarin, and the Supreme Court agreed to resolve the issue.
If the Court rules for Amarin, manufacturers using skinny labels could face greater legal risk. Generic companies might avoid the faster, cheaper skinny-label pathway, instead waiting for all patents to expire or adopting riskier strategies to reduce exposure. That would likely delay generic competition and keep prices higher longer. The Crestor example is illustrative: multiple patents could have preserved its monopoly until 2022, but skinny labeling permitted competition beginning in 2016, producing substantial short-term savings for patients and insurers.
Legal experts warn that extended monopolies can raise costs, reduce access to medicines, and worsen health outcomes. Others note that the financial incentives to use skinny labels are strong, and companies may find ways to manage increased litigation risk rather than abandon the tactic entirely.
If the Court sides with Hikma, immediate price effects are unlikely. Amarin contends, however, that a decision favoring generics could weaken incentives for brand manufacturers to invest in developing new indications or additional drug uses, potentially slowing future medical innovation.
Observers point to factors that may favor Hikma: a supportive solicitor general brief, the Supreme Court’s history of reversing some lower-court patent rulings, and recent decisions that signal caution in broad inducement liability. Still, scholars urge caution in predicting the outcome: the Court could issue a broad ruling protecting generics, a narrow decision preserving the status quo, or a decision that recalibrates how companies approach labeling and marketing. Reporting for this story was supported in part by Arnold Ventures. Leslie Walker is a senior reporter for Tradeoffs, a nonprofit news organization covering health‑care tradeoffs.